[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335159-105":59,"doc-detail-335159-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pd-1-inhibitor-combined-with-sbrt-gm-csf-and-thymosin-alpha-1-in-metastatic-breast-cancer-a-case-report-and-literature-review","PD-1 inhibitor combined with SBRT, GM-CSF, and thymosin alpha-1 in metastatic breast cancer - A case report and literature review","","Triple-negative breast cancer has a poorer prognosis than other subtypes, particularly in pretreated metastatic disease, and limited options drive investigation of novel protocols. A 48-year-old woman with lung-metastatic mTNBC refractory to multiple prior therapies entered a clinical trial combining stereotactic body radiotherapy with immunotherapy, GM-CSF, and thymosin alpha-1, achieving notable efficacy with abscopal effects. RECIST v1.1 showed partial response, with regression rates of −78.97% (target) and −56.73% (observed lesions), stable hematology, no myelosuppression, CA-199 reduction, and only grade 2 skin reaction that improved with antiallergic treatment.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pd-1-inhibitor-combined-with-sbrt-gm-csf-and-thymosin-alpha-1-in-metastatic-breast-cancer-a-case-report-and-literature-review/335159/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pd-1-inhibitor-combined-with-sbrt-gm-csf-and-thymosin-alpha-1-in-metastatic-breast-cancer-a-case-report-and-literature-review/335159.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What patient and disease details were described in the case report?","Question",{"text":112,"@type":113},"The report describes a 48-year-old female with lung-metastatic metastatic triple-negative breast cancer (mTNBC) who had not responded to multiple prior lines of therapy including surgery, chemotherapy, and radiotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What treatment combination was used in the clinical trial?",{"text":117,"@type":113},"The regimen combined stereotactic body radiotherapy (SBRT) with immunotherapy (PD-1 inhibitor), granulocyte-macrophage colony-stimulating factor (GM-CSF), and thymosin alpha-1 to treat previously treated metastatic solid cancers.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes and response measures were reported?",{"text":121,"@type":113},"Using RECIST v1.1, the patient achieved partial response, with regression rates of −78.97% for the target lesion and −56.73% for observed lesions after two cycles. Hematological indexes remained stable with no apparent myelosuppression, CA-199 decreased, and only a grade 2 skin reaction occurred that improved after antiallergic treatment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335159,1790216851,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":24,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","®  \n Clinical Case Report   \nPD-1 inhibitor combined with SBRT, GM-CSF, and thymosin alpha-1 in metastatic breast cancer A case report and literature review  \nJiamin Yu, MMa ,b , Qiang Wang, MDc , Lijun Wang, MDa ,b , Dan Zong, MDa ,b , Xia He, MDa ,b ,*  \n\n| Abstract\u003Cbr>Rationale: Triple-negative breast cancer is characterized by a worse prognosis compared with other breast cancer subtypes, especially in the case of pretreated metastatic triple-negative breast cancer (mTNBC) . Because of the limited treatment options and suboptimal response rates, there is a pressing need to explore novel treatment protocols.\u003Cbr>Patient concerns: A 48-year-old female patient diagnosed with mTNBC who had not responded to multiple lines of therapy (including surgery, chemotherapy, and radiotherapy) but demonstrated significant efficacy and abscopal effects after enrolling in our clinical trial.\u003Cbr>Diagnoses: Triple-negative breast cancer with lung metastases.\u003Cbr>Interventions: The clinical trial combined stereotactic body radiotherapy, immunotherapy, granulocyte-macrophage colonystimulating factor, and thymosin alpha-1 to treat previously treated metastatic solid cancers.\u003Cbr>Outcomes: This combined treatment regimen implemented in this clinical trial yielded the patient’s notable efficacy, accompanied by abscopal effects. The target lesion and the 3 observed lesions achieved a partial response according to the RECIST v1 .1 criteria. reevaluation scans after 2 cycles of immunotherapy indicated a regression rate of −78.97% for the target lesion and −56.73% for the observed lesions. Hematological indexes were stable, and there was no apparent myelosuppression. Also, the tumor marker CA-199 exhibited a downward trend. During the course of treatment, the patient experienced a grade 2 skin reaction, which improved after receiving antiallergic treatment. No further adverse effects were observed.\u003Cbr>Lessons: This treatment regimen may offer a promising treatment strategy for patients with mTNBC and other metastatic solid cancers.\u003Cbr>Abbreviations: ER- = negative estrogen receptor, GM-CSF = granulocyte-macrophage colony-stimulating factor, HER2- = negative human epidermal growth factor receptor 2, mTNBC = metastatic triple-negative breast cancer, PD = progressive disease, PFS = progression-free survival, PR- = negative progesterone receptor, PR = partial response, RT = radiotherapy, immunotherapy, SBRT = stereotactic body radiotherapy, TME = tumor microenvironment, TNBC- = Triple-negative breast cancer, Treg = regulatory T. |\n| --- |\n| Keywords: granulocyte-macrophage colony-stimulating factor (GM-CSF) , immunotherapy, metastatic triple-negative breast cancer (mTNBC), refractory solid cancers, stereotactic body radiotherapy (SBRT), thymosin alpha-1, triple-negative breast cancer (TNBC) |\n\nJY and QW contributed equally to this work.  \nThis work was supported by Nanjing Science and Technology Plan Project (no. 2022SX00001663); Wu Jieping Medical Foundation Project (no. 320.6750.2021- 10-52); and National Natural Science Foundation of China (no. 82172804). Informed consent was obtained prior to each treatment in this case report.  \nWritten informed consent has been obtained from the patient for the release of relevant clinical and imaging data from their cases, included consent for the publication of the case details.  \nThe authors have no conflicts of interest to disclose.  \nData sharing not applicable to this article as no datasets were generated or analyzed during the current study.  \nThis study was approved by the Ethics Committee of Jiangsu Cancer Hospital and Xuzhou Cancer Hospital and registered at Chinese Clinical Trial Registry (ChiCTR2200062706).  \na Department of Radiotherapy, The Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China, b Department of Environmental Genomics, Jiangsu Key Laboratory  \nof Cancer Biomarkers, Prevention and Treatment, Collaborative","cbCailYMFpgTjzHH","https://ap.wps.com/l/cbCailYMFpgTjzHH","pdf",780390,"English","# Introduction\n## Triple-negative breast cancer background\n## Prognosis and treatment rationale","[{\"question\":\"What patient and disease details were described in the case report?\",\"answer\":\"The report describes a 48-year-old female with lung-metastatic metastatic triple-negative breast cancer (mTNBC) who had not responded to multiple prior lines of therapy including surgery, chemotherapy, and radiotherapy.\"},{\"question\":\"What treatment combination was used in the clinical trial?\",\"answer\":\"The regimen combined stereotactic body radiotherapy (SBRT) with immunotherapy (PD-1 inhibitor), granulocyte-macrophage colony-stimulating factor (GM-CSF), and thymosin alpha-1 to treat previously treated metastatic solid cancers.\"},{\"question\":\"What outcomes and response measures were reported?\",\"answer\":\"Using RECIST v1.1, the patient achieved partial response, with regression rates of −78.97% for the target lesion and −56.73% for observed lesions after two cycles. Hematological indexes remained stable with no apparent myelosuppression, CA-199 decreased, and only a grade 2 skin reaction occurred that improved after antiallergic treatment.\"}]","PD-1 inhibitor combined with SBRT, GM-CSF, and thymosin alpha-1 in metastatic breast cancer - A case report and literature review | PDF",1790009832,13]